John G.F. Cleland

TL;DR: The PARADIGM-HF trial showed unequivocal superiority of sacubitril–valsartan over enalapril in clinically stable patients with heart failure, a reduced ejection fraction (HFrEF) and mostly mild symptoms who were initially able to tolerate the protocol-specified target doses of each agent.

TL;DR: New criteria for the electrocardiographic diagnosis of left ventricular hypertrophy (LVH) are set out, namely (max Samp + SV4 amp) ≥2.8 mV and 2.3 MV in male and female patients, respectively.

TL;DR: In this article, the prognostic significance of late gadolinium enhancement (LGE) in patients without coronary artery disease and with normal range left ventricula was investigated, and the results showed that LGE significantly improved the prognosis.

TL;DR: In the future, the variability of ultrasound measurements of carotid IMT are likely to be reduced by further development of automatic calculation of this index by magnetic resonance imaging, as well as methodologic problems related to intra- and interobserver variability make this index not adequately reproducible when tracking the progression ofcarotid atherosclerosis.

TL;DR: In this article , the authors examined the effect of the cardiac myosin activator omecamtiv mecarbil according to baseline NT-proBNP level in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure trial (GALACTIC‐HF).